Quick Answer
Oruka Therapeutics, Inc. reported Diluted EPS of $3.87 per share (loss) for fiscal year 2024.
Oruka Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$3.87 | -945.9% |
| 2023 | -$0.37 | +46.4% |
| 2022 | -$0.69 | +50.4% |
| 2021 | -$1.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$0.46 | +93.4% | -15.0% |
| March 31, 2025 | -$0.40 | +81.9% | +72.6% |
| September 30, 2024 | -$1.46 | -1360.0% | +79.0% |
| June 30, 2024 | -$6.96 | -6860.0% | -214.9% |
| March 31, 2024 | -$2.21 | -2355.6% | -2110.0% |
| September 30, 2023 | -$0.10 | +37.5% | +0.0% |
| June 30, 2023 | -$0.10 | +54.5% | -11.1% |
| March 31, 2023 | -$0.09 | +60.9% | +43.8% |
- Oruka Therapeutics, Inc. showed a decrease of -945.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Oruka Therapeutics, Inc.’s diluted eps has declined by 178.4% (from $1.39 per share (loss) to $3.87 per share (loss)).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 6, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: